中药干预PPARγ及其通路治疗心肌缺血再灌注损伤的研究进展
摘要
<正>急性心肌梗死(acute myocardial infarction,AMI)目前仍然是全球导致死亡的主要原因[1-2]。世界卫生组织的数据显示,由于缺血性心脏病,特别是急性心肌梗死,估计每年有700多万人死亡。AMI的有效治疗措施是通过溶栓或经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)尽快恢复病变心肌的有效血液供应,从而减少心肌坏死,防止心室重构,改善心功能,减少心律失常,有效降低病死率。然而缺血心肌恢复再灌注后,因再灌注损伤产生心肌形态及功能异常变化,甚至可能使部分缺血存活的心肌细胞坏死而死
引文
[1]Go AS,Mozaffarian D,Roger VL,et al.Heart disease and stroke statistics-2013 update:a report from the American Heart Association[J].Circulation,2013,127(1):e6-e245.
[2]Lopez AD,Murray CC.The global burden of disease 1990-2020.Nat Med,1998(4):1241-1243.
[3]Lucchesi BR,Werns SW,Fantone JC.The role of the neutrophil and free radicals in ischemic myocardial injury[J].J Mol Cell Cardiol,1989,21:1241-1251.
[4]Rodrigo R,Libuy M,Feliu F,et al.Oxidative stress-related biomarkers in essential hypertension and ischemia-reperfusion myocardial damage[J].Dis Markers,2013,35:773-790.
[5]Petrosillo G,Ruggiero FM,Di Venosa N,et al.Decreased complexⅢactivity in mitochondria isolated from rat heart subjected to ischemia and reperfusion:role of reactive oxygen species and cardiolipin[J].FASEB J,2003(7):14-16.
[6]Reimer KA,Tanaka M,Murry CE,et al.Evaluation of free radical injury in myocardium[J].Toxicol Pathol,1990,18:470-480.
[7]Richard VJ,Murry CE,Jennings RB,et al.Oxygen-derived free radicals and postischemic myocardial reperfusion:therapeutic implications[J].Fundam Clin Pharmacol,1990(4):85-103.
[8]Levick SP,Gardner JD,Holland M,et al.Protection from adverse myocardial remodeling secondary to chronic volume overload in mast cell defi cient rats[J].J Mol Cell Cardiol,2008,45:56-61.
[9]Meldrum DR.Tumor necrosis factor in the heart[J].Am J Physiol,1998,274:R577-595.
[10]Ruisong M,Xiaorong H,Gangying H,et al.The Protective role of interleukin-33 in myocardial ischemia and reperfusion is associated with decreased HMGB1 expression and up-regulation of the P38MAPK signaling pathway[J].PloS One,2015,10:e0143064.
[11]Prasad A,Stone GW,Holmes DR,et al.Reperfusion injury,microvascular dysfunction,and cardioprotection:the“dark side”of reperfusion[J].Circulation,2009,120:2105-2012.
[12]Nakagawa T,Shimizu S,Watanabe T,et al.Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death[J].Nature,2005,434:652-658.
[13]王凌燕,蔡高军,孙文伟,等.脂质载体前列腺素E1对大鼠心肌缺血-再灌注损伤的保护作用[J].中国实验诊断学,2006,10(3):255-257.
[14]Pavione MA,Carmona F,De CM,et al.Late remote ischemic preconditioning in children undergoing cardiopulmonary bypass:a randomized controlled trial[J].Journal of Thoracic&Cardiovascular Surgery,2012,144(1):178-183.
[15]Hu X,Zhang K,Xu C,et al.Anti-inflammatory effect of sodium butyrate preconditioning during myocardial ischemia/reperfusion[J].Exp Ther Med,2014(8):229-232.
[16]Speyer CL,Ward PA.Role of endothelial chemokines and their receptors during inflammation[J].J Invest Surg,2011,24:18-27.
[17]Dreyer WJ,Smith CW,Michael LH,et al.Canine neutrophil activation by cardiac lymph obtained during reperfusion of ischemic myocardium[J].Circ Res,1989,65:1751-1762.
[18]Elgebaly SA,Hashmi FH,Houser SL,et al.Cardiac-derived neutrophil chemotactic factors:detection in coronary sinus effluents of patients undergoing myocardial revascularization[J].J Thorac Cardiovasc Surg,1992,103:952-959.
[19]Jordan JE,Zhao ZQ,Vinten-Johansen J.The role of neutrophils in myocardial ischemia-reperfusion injury[J].Cardiovascular Research,1999,43:860-878.
[20]Itoh S,Kimura N,Axtell RC,et al.Interleukin-17 accelerates allograft rejection by suppressing regulatory T cell expansion[J].Circulation,2011,124:S187-196.
[21]Guo J,Wang SB,Yuan TY,et al.Coptisine protects rat heart against myocardial ischemia/reperfusion injury by suppressing myocardial apoptosis and inflammation[J].Atherosclerosis,2013,231:384-391.
[22]Zhu H,Li J,Wang S,et al.Hmgb1-TLR4-IL-23-IL-17A axis promote ischemia-reperfusion injury in a cardiac transplantation model[J].Transplantation,2013,95:1448-1454.
[23]Zhang A,Mao X,Li L,et al.Necrostatin-1 inhibits Hmgb1-IL-23/IL-17 pathway and attenuates cardiac ischemia reperfusion injury[J].Transpl Int,2014,27:1077-1085.
[24]Wei G,Guan Y,Yin Y,et al.Anti-inflammatory effect of protocatechuic aldehyde on myocardial ischemia/reperfusion injury in vivo and in vitro[J].Inflammation,2013,36:592-602.
[25]Yang J,Jiang H,Yang J,et al.Valsartan preconditioning protects against myocardial ischemia-reperfusion injury through TLR4/NF-kappaB signaling pathway[J].Mol Cell Biochem,2009,330:39-46.
[26]Varela LM,Ortega-Gomez A,Lopez S,et al.The effects of dietary fatty acids on the postprandial triglyceride-rich lipoprotein/apo B48receptor axis in human monocyte/macrophage cells[J].J Nutr Biochem,2013,24:2031-2039.
[27]Khimenko PL,Bagby GJ,Fuseler J,et al.Tumor necrosis factor-alpha in ischemia and reperfusion injury in rat lungs[J].J Appl Physiol(1985),1998,85:2005-2011.
[28]Rider P,Carmi Y,Guttman O,et al.IL-1alpha and IL-1beta recruit different myeloid cells and promote different stages of sterile inflammation[J].J Immunol,2011,187:4835-4843.
[29]Marchant DJ,Boyd JH,Lin DC,et al.Inflammation in myocardial diseases[J].Circ Res,2012,110:126-144.
[30]Swirski FK,Nahrendorf M.Leukocyte behavior in atherosclerosis,myocardial infarction,and heart failure[J].Science,2013,339:161-166.
[31]Pathmanathan S,Krishna MT,Blomberg A,et al.Repeated daily exposure to 2 ppm nitrogen dioxide upregulates the expression of IL-5,IL-10,IL-13,and ICAM-1 in the bronchial epithelium of healthy human airways[J].Occup Environ Med,2003,60:892-896.
[32]Marrero MB,Venema VJ,He H,et al.Inhibition by the JAK/STAT pathway of IFNgamma-and LPS-stimulated nitricoxide synthase induction in vascular smooth muscle cell[J].Biochem Biophys Res Commun,1998,252:508-512.
[33]Ren JY,Song JX,Lu MY,et al.Cardioprotection by ischemic postconditioning is lost in isolated perfused heart from diabetic rats:Involvement of transient receptor potential vanilloid 1,calcitonin gene-related peptide and substance P[J].Regul Pept,2011,169:49-57.
[34]Saini HK,Xu YJ,Zhang M,et al.Role of tumour necrosis factor-alpha and other cytokines in ischemia-reperfusion-induced injury in the heart[J].Experimental and Clinical Cardiology,2005,10:213-222.
[35]Burne MJ,Elghandour A,Haq M,et al.IL-1 and TNF independent pathways mediate ICAM-1/VCAM-1 up-regulation in ischemia reperfusion injury[J].J Leukoc Biol,2001,70:192-198.
[36]Lin Y,Chen L,Li W,et al.Role of high-mobility group box-1 in myocardial ischemia/reperfusion injury and the effect of ethyl pyruvate[J].Exp Ther Med,2015,9:1537-1541.
[37]Hu H,Zhai C,Qian G,et al.Protective effects of tanshinone IIA on myocardial ischemia reperfusion injury by reducing oxidative stress,HMGB1 expression and inflammatory reaction[J].Pharm Biol,2015,53:1752-1758.
[38]Zhang R,Wugeti N,Sun J,et al.Effects of vagus nerve stimulation via cholinergic anti-inflammatory pathway activation on myocardial ischemia/reperfusion injury in canine[J].Int J Clin Exp Med,2014(7):2615-2623.
[39]Anselmi A,Abbate A,Girola F,et al.Myocardial ischemia,stunning,inflammation,and apoptosis during cardiac surgery:a review of evidence[J].Eur J Cardiothorac Surg,2004,25:304-311.
[40]高妮妮,王芳,廉哲勋.P13K-Akt-e NOS信号通路在三磷酸腺苷后处理减轻兔心肌缺血再灌注损伤中的作用[J].中国循环杂志,2014,29:59-63.
[41]Staels B,Koenig W,Habib A,et al.Activation of human aortic smooth-muscle cells is inhibited by PPARαbut not by PPARγactivators[J].Nature(London),1998,393:790-793.
[42]Marx N,Sch9nbeck U,Lazar MA,et al.Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells[J].Circ Res,1998,83:1097-1103.
[43]Marchant DJ,Boyd JH,Lin DC,et al.Inflammation in myocardial diseases[J].Circ Res,2012,110:126-144.
[44]Swirski FK,Nahrendorf M.Leukocyte behavior in atherosclerosis,myocardial infarction,and heart failure[J].Science,2013,339:161-166.
[45]Marrero MB,Venema VJ,He H,et al.Inhibition by the JAK/STAT pathway of IFNgamma-and LPS-stimulated nitricoxide synthase induction in vascular smooth muscle cell[J].Biochem Biophys Res Commun,1998,252:508-512.
[46]Blanquart C,Barbier O,Fruchart JC,et al.Peroxisome proliferator-activated receptors:regulation of transcriptional activities and roles in inflammation[J].J Steroid Biochem Mol Biol,2003,85:267.
[47]Youssef J,Badr M.Role of peroxisome proliferator-activated receptors in inflammationcontrol[J].J Biomed Biotechnol,2004(3):156.
[48]高凌云,何作云,牟娇.罗格列酮对apoE敲除小鼠血浆高敏C反应蛋白水平的影响[J].重庆医学,2006,35(6):515.
[49]Morgan MJ,Liu ZG.Crosstalk of reactive oxygen species and NF-kappaB signaling[J].Cell Res,2011,21:103-115.
[50]Gordon JW,Shaw JA,Kirshenbaum LA.Multiple facets of NF-kappaB in the heart:to be or not to NF-kappaB[J].Circ Res,2011,108:1122-1132.
[51]Liu X,Yu Z,Huang X,et al.Peroxisome proliferator-activated receptorγ(PPARγ)mediates the protective effect of quercetin against myocardial schemia-reperfusion injury via suppressing the NF-κB pathway[J].Am J Transl Res,2016(8):5169-5186.
[52]Duan SZ,Usher MG,Mortensen RM.Peroxisome proliferatoractivated receptor-gamma-mediated effects in the vasculature[J].Circ Res,2008,102:283-294.
[54]Li M,Pascual G,Glass CK.Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene[J].Mol Cell Biol,2000,20:4699-4707.
[54]Chung SW,Kang BY,Kim SH,et al.Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor-gamma and nuclear factor-kappa B[J].J Biol Chem,2000,275:32681-32687.
[55]Ricote M,Glass CK.PPARs and molecular mechanisms of transrepression[J].Biochim Biophys Acta,2007,1771:926-935.
[56]Kodera Y,Takeyama K,Murayama A,et al.Ligand type-specific interactions of peroxisome proliferatoractivated receptor gamma with transcriptional coactivators[J].J Biol Chem,2000,275:33201-33204.
[57]Delerive P,De Bosscher K,Besnard S,et al.Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1[J].J Biol Chem,1999,274:32048-32054.
[58]Li M,Pascual G,Glass CK.Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene[J].Mol Cell Biol,2000,20:4699-4707.
[59]Ricote M,Li AC,Willson TM,et al.The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation[J].Nature,1998,391:79-82.
[60]Bocos C,Gottlicher M,Gearing K,et al.Fatty acid activation of peroxisome proliferator-activated receptor(PPAR)[J].J Steroid Biochem Mol Biol,1995,53(1-6):467-473.
[61]Powell WS.15-Deoxy-delta12,14-PGJ2:endogenousvPPAR-gamma ligand or minor eicosanoid degradation product[J].J Clin Invest,2003,112:828-830.
[62]Yue Tl TL,Chen J,Bao W,et al.In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone[J].Circulation,2001,104:2588-2594.
[63]Willson TM,Cobb JE,Cowan DJ,et al.The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones[J].JMed Chem,1996,39(3):665-668.
[64]Morgan MJ,Liu ZG.Crosstalk of reactive oxygen species and NF-kappaB signaling[J].Cell Res,2011,21:103-115.
[65]Yki-Jrvinen H.Thiazolidinediones.N Engl J Med,2004,351:1106-1118.
[66]Glintborg D,Andersen M,Hagen C,et al.Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome:A randomized,placebocontrolled trial[J].J Clin Endocrinol Metab,2008,93:1696-1670.
[67]Raskin P,Rendell M,Riddle MC,et al.A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulintreated type 2 diabetes[J].Diabetes Care,2001,24:1226-1232.
[68]Aronoff S,Rosenblatt S,Braithwaite S,et al.Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes:A 6-month randomized placebo-controlled dose-response study.The Pioglitazone 001 Study Group[J].Diabetes Care,2000,23:1605-1611.
[69]Nissen SE,Wolski K.Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes[J].N Engl JMed,2007,356:2457-2471.
[70]Dormandy JA,Charbonnel B,Eckland DJ,et al.PROactive Investigators:Secondary prevention of macrovascular events in patients with type 2 diabetes in the proactive study(prospective pioglitazone clinical trial in macrovascular events):A randomised controlled trial[J].Lancet,2005,366:1279-1289.
[71]Nissen SE,Wolski K.Rosiglitazone revisited:An updated meta-analysis of risk for myocardial infarction and cardiovascular mortality[J].Arch Intern Med,2010,170:1191-1201.
[72]刘红缨,孙爱军,王时俊,等.丹参酚酸B通过激活过氧化体增殖物激活型受体γ抑制树突状细胞免疫成熟的作用及其机制[J].中国动脉硬化杂志,2011(3):265.
[73]王子超,赵丽娟.姜黄素对NAFLD大鼠肝组织PPAR-γ和NF-κB p65 mRNA及蛋白表达的影响[J].中国医科大学学报,2016,45(2):120-126.
[74]郭杨志,杜娟,李向民,等.黄连对糖尿病肾病大鼠肾脏NF-κB及PPAR-γ表达的影响[J].世界中医药,2017(4):171-174.
[75]平键,陈红云,周扬,等.毛蕊异黄酮上调过氧化物酶体增殖因子活化受体γ抑制大鼠肝星状细胞活化的研究[J].中国中药杂志,2015,40(12):2383-2388.
[76]朱磊.清肠化湿、益气健脾法序贯治疗溃疡性结肠炎疗效观察及调控PPAR-γ、NF-κB的实验研究[D].南京中医药大学,2009.
[77]沈宇清,贾典荣,曹云,等.通解口服液对MODS模型大鼠回肠PPAR-γ、AP-1、NF-κB表达的影响[J].江苏中医药,2015(4):78-81.
[78]朱向东,梅晓云,王燕,等.痛泻要方对溃疡性结肠炎大鼠结肠黏膜PPAR-γ基因和蛋白表达的影响[J].中华中医药杂志,2013(4):941-945.
[79]王洁,王亚南,陆妍,等.藤莓汤对胶原诱导性关节炎大鼠滑膜PPARγ/NF-κB信号途径的影响[J].中国中西医结合杂志,2017(4):75-80.
[2]Lopez AD,Murray CC.The global burden of disease 1990-2020.Nat Med,1998(4):1241-1243.
[3]Lucchesi BR,Werns SW,Fantone JC.The role of the neutrophil and free radicals in ischemic myocardial injury[J].J Mol Cell Cardiol,1989,21:1241-1251.
[4]Rodrigo R,Libuy M,Feliu F,et al.Oxidative stress-related biomarkers in essential hypertension and ischemia-reperfusion myocardial damage[J].Dis Markers,2013,35:773-790.
[5]Petrosillo G,Ruggiero FM,Di Venosa N,et al.Decreased complexⅢactivity in mitochondria isolated from rat heart subjected to ischemia and reperfusion:role of reactive oxygen species and cardiolipin[J].FASEB J,2003(7):14-16.
[6]Reimer KA,Tanaka M,Murry CE,et al.Evaluation of free radical injury in myocardium[J].Toxicol Pathol,1990,18:470-480.
[7]Richard VJ,Murry CE,Jennings RB,et al.Oxygen-derived free radicals and postischemic myocardial reperfusion:therapeutic implications[J].Fundam Clin Pharmacol,1990(4):85-103.
[8]Levick SP,Gardner JD,Holland M,et al.Protection from adverse myocardial remodeling secondary to chronic volume overload in mast cell defi cient rats[J].J Mol Cell Cardiol,2008,45:56-61.
[9]Meldrum DR.Tumor necrosis factor in the heart[J].Am J Physiol,1998,274:R577-595.
[10]Ruisong M,Xiaorong H,Gangying H,et al.The Protective role of interleukin-33 in myocardial ischemia and reperfusion is associated with decreased HMGB1 expression and up-regulation of the P38MAPK signaling pathway[J].PloS One,2015,10:e0143064.
[11]Prasad A,Stone GW,Holmes DR,et al.Reperfusion injury,microvascular dysfunction,and cardioprotection:the“dark side”of reperfusion[J].Circulation,2009,120:2105-2012.
[12]Nakagawa T,Shimizu S,Watanabe T,et al.Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death[J].Nature,2005,434:652-658.
[13]王凌燕,蔡高军,孙文伟,等.脂质载体前列腺素E1对大鼠心肌缺血-再灌注损伤的保护作用[J].中国实验诊断学,2006,10(3):255-257.
[14]Pavione MA,Carmona F,De CM,et al.Late remote ischemic preconditioning in children undergoing cardiopulmonary bypass:a randomized controlled trial[J].Journal of Thoracic&Cardiovascular Surgery,2012,144(1):178-183.
[15]Hu X,Zhang K,Xu C,et al.Anti-inflammatory effect of sodium butyrate preconditioning during myocardial ischemia/reperfusion[J].Exp Ther Med,2014(8):229-232.
[16]Speyer CL,Ward PA.Role of endothelial chemokines and their receptors during inflammation[J].J Invest Surg,2011,24:18-27.
[17]Dreyer WJ,Smith CW,Michael LH,et al.Canine neutrophil activation by cardiac lymph obtained during reperfusion of ischemic myocardium[J].Circ Res,1989,65:1751-1762.
[18]Elgebaly SA,Hashmi FH,Houser SL,et al.Cardiac-derived neutrophil chemotactic factors:detection in coronary sinus effluents of patients undergoing myocardial revascularization[J].J Thorac Cardiovasc Surg,1992,103:952-959.
[19]Jordan JE,Zhao ZQ,Vinten-Johansen J.The role of neutrophils in myocardial ischemia-reperfusion injury[J].Cardiovascular Research,1999,43:860-878.
[20]Itoh S,Kimura N,Axtell RC,et al.Interleukin-17 accelerates allograft rejection by suppressing regulatory T cell expansion[J].Circulation,2011,124:S187-196.
[21]Guo J,Wang SB,Yuan TY,et al.Coptisine protects rat heart against myocardial ischemia/reperfusion injury by suppressing myocardial apoptosis and inflammation[J].Atherosclerosis,2013,231:384-391.
[22]Zhu H,Li J,Wang S,et al.Hmgb1-TLR4-IL-23-IL-17A axis promote ischemia-reperfusion injury in a cardiac transplantation model[J].Transplantation,2013,95:1448-1454.
[23]Zhang A,Mao X,Li L,et al.Necrostatin-1 inhibits Hmgb1-IL-23/IL-17 pathway and attenuates cardiac ischemia reperfusion injury[J].Transpl Int,2014,27:1077-1085.
[24]Wei G,Guan Y,Yin Y,et al.Anti-inflammatory effect of protocatechuic aldehyde on myocardial ischemia/reperfusion injury in vivo and in vitro[J].Inflammation,2013,36:592-602.
[25]Yang J,Jiang H,Yang J,et al.Valsartan preconditioning protects against myocardial ischemia-reperfusion injury through TLR4/NF-kappaB signaling pathway[J].Mol Cell Biochem,2009,330:39-46.
[26]Varela LM,Ortega-Gomez A,Lopez S,et al.The effects of dietary fatty acids on the postprandial triglyceride-rich lipoprotein/apo B48receptor axis in human monocyte/macrophage cells[J].J Nutr Biochem,2013,24:2031-2039.
[27]Khimenko PL,Bagby GJ,Fuseler J,et al.Tumor necrosis factor-alpha in ischemia and reperfusion injury in rat lungs[J].J Appl Physiol(1985),1998,85:2005-2011.
[28]Rider P,Carmi Y,Guttman O,et al.IL-1alpha and IL-1beta recruit different myeloid cells and promote different stages of sterile inflammation[J].J Immunol,2011,187:4835-4843.
[29]Marchant DJ,Boyd JH,Lin DC,et al.Inflammation in myocardial diseases[J].Circ Res,2012,110:126-144.
[30]Swirski FK,Nahrendorf M.Leukocyte behavior in atherosclerosis,myocardial infarction,and heart failure[J].Science,2013,339:161-166.
[31]Pathmanathan S,Krishna MT,Blomberg A,et al.Repeated daily exposure to 2 ppm nitrogen dioxide upregulates the expression of IL-5,IL-10,IL-13,and ICAM-1 in the bronchial epithelium of healthy human airways[J].Occup Environ Med,2003,60:892-896.
[32]Marrero MB,Venema VJ,He H,et al.Inhibition by the JAK/STAT pathway of IFNgamma-and LPS-stimulated nitricoxide synthase induction in vascular smooth muscle cell[J].Biochem Biophys Res Commun,1998,252:508-512.
[33]Ren JY,Song JX,Lu MY,et al.Cardioprotection by ischemic postconditioning is lost in isolated perfused heart from diabetic rats:Involvement of transient receptor potential vanilloid 1,calcitonin gene-related peptide and substance P[J].Regul Pept,2011,169:49-57.
[34]Saini HK,Xu YJ,Zhang M,et al.Role of tumour necrosis factor-alpha and other cytokines in ischemia-reperfusion-induced injury in the heart[J].Experimental and Clinical Cardiology,2005,10:213-222.
[35]Burne MJ,Elghandour A,Haq M,et al.IL-1 and TNF independent pathways mediate ICAM-1/VCAM-1 up-regulation in ischemia reperfusion injury[J].J Leukoc Biol,2001,70:192-198.
[36]Lin Y,Chen L,Li W,et al.Role of high-mobility group box-1 in myocardial ischemia/reperfusion injury and the effect of ethyl pyruvate[J].Exp Ther Med,2015,9:1537-1541.
[37]Hu H,Zhai C,Qian G,et al.Protective effects of tanshinone IIA on myocardial ischemia reperfusion injury by reducing oxidative stress,HMGB1 expression and inflammatory reaction[J].Pharm Biol,2015,53:1752-1758.
[38]Zhang R,Wugeti N,Sun J,et al.Effects of vagus nerve stimulation via cholinergic anti-inflammatory pathway activation on myocardial ischemia/reperfusion injury in canine[J].Int J Clin Exp Med,2014(7):2615-2623.
[39]Anselmi A,Abbate A,Girola F,et al.Myocardial ischemia,stunning,inflammation,and apoptosis during cardiac surgery:a review of evidence[J].Eur J Cardiothorac Surg,2004,25:304-311.
[40]高妮妮,王芳,廉哲勋.P13K-Akt-e NOS信号通路在三磷酸腺苷后处理减轻兔心肌缺血再灌注损伤中的作用[J].中国循环杂志,2014,29:59-63.
[41]Staels B,Koenig W,Habib A,et al.Activation of human aortic smooth-muscle cells is inhibited by PPARαbut not by PPARγactivators[J].Nature(London),1998,393:790-793.
[42]Marx N,Sch9nbeck U,Lazar MA,et al.Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells[J].Circ Res,1998,83:1097-1103.
[43]Marchant DJ,Boyd JH,Lin DC,et al.Inflammation in myocardial diseases[J].Circ Res,2012,110:126-144.
[44]Swirski FK,Nahrendorf M.Leukocyte behavior in atherosclerosis,myocardial infarction,and heart failure[J].Science,2013,339:161-166.
[45]Marrero MB,Venema VJ,He H,et al.Inhibition by the JAK/STAT pathway of IFNgamma-and LPS-stimulated nitricoxide synthase induction in vascular smooth muscle cell[J].Biochem Biophys Res Commun,1998,252:508-512.
[46]Blanquart C,Barbier O,Fruchart JC,et al.Peroxisome proliferator-activated receptors:regulation of transcriptional activities and roles in inflammation[J].J Steroid Biochem Mol Biol,2003,85:267.
[47]Youssef J,Badr M.Role of peroxisome proliferator-activated receptors in inflammationcontrol[J].J Biomed Biotechnol,2004(3):156.
[48]高凌云,何作云,牟娇.罗格列酮对apoE敲除小鼠血浆高敏C反应蛋白水平的影响[J].重庆医学,2006,35(6):515.
[49]Morgan MJ,Liu ZG.Crosstalk of reactive oxygen species and NF-kappaB signaling[J].Cell Res,2011,21:103-115.
[50]Gordon JW,Shaw JA,Kirshenbaum LA.Multiple facets of NF-kappaB in the heart:to be or not to NF-kappaB[J].Circ Res,2011,108:1122-1132.
[51]Liu X,Yu Z,Huang X,et al.Peroxisome proliferator-activated receptorγ(PPARγ)mediates the protective effect of quercetin against myocardial schemia-reperfusion injury via suppressing the NF-κB pathway[J].Am J Transl Res,2016(8):5169-5186.
[52]Duan SZ,Usher MG,Mortensen RM.Peroxisome proliferatoractivated receptor-gamma-mediated effects in the vasculature[J].Circ Res,2008,102:283-294.
[54]Li M,Pascual G,Glass CK.Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene[J].Mol Cell Biol,2000,20:4699-4707.
[54]Chung SW,Kang BY,Kim SH,et al.Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor-gamma and nuclear factor-kappa B[J].J Biol Chem,2000,275:32681-32687.
[55]Ricote M,Glass CK.PPARs and molecular mechanisms of transrepression[J].Biochim Biophys Acta,2007,1771:926-935.
[56]Kodera Y,Takeyama K,Murayama A,et al.Ligand type-specific interactions of peroxisome proliferatoractivated receptor gamma with transcriptional coactivators[J].J Biol Chem,2000,275:33201-33204.
[57]Delerive P,De Bosscher K,Besnard S,et al.Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1[J].J Biol Chem,1999,274:32048-32054.
[58]Li M,Pascual G,Glass CK.Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene[J].Mol Cell Biol,2000,20:4699-4707.
[59]Ricote M,Li AC,Willson TM,et al.The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation[J].Nature,1998,391:79-82.
[60]Bocos C,Gottlicher M,Gearing K,et al.Fatty acid activation of peroxisome proliferator-activated receptor(PPAR)[J].J Steroid Biochem Mol Biol,1995,53(1-6):467-473.
[61]Powell WS.15-Deoxy-delta12,14-PGJ2:endogenousvPPAR-gamma ligand or minor eicosanoid degradation product[J].J Clin Invest,2003,112:828-830.
[62]Yue Tl TL,Chen J,Bao W,et al.In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone[J].Circulation,2001,104:2588-2594.
[63]Willson TM,Cobb JE,Cowan DJ,et al.The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones[J].JMed Chem,1996,39(3):665-668.
[64]Morgan MJ,Liu ZG.Crosstalk of reactive oxygen species and NF-kappaB signaling[J].Cell Res,2011,21:103-115.
[65]Yki-Jrvinen H.Thiazolidinediones.N Engl J Med,2004,351:1106-1118.
[66]Glintborg D,Andersen M,Hagen C,et al.Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome:A randomized,placebocontrolled trial[J].J Clin Endocrinol Metab,2008,93:1696-1670.
[67]Raskin P,Rendell M,Riddle MC,et al.A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulintreated type 2 diabetes[J].Diabetes Care,2001,24:1226-1232.
[68]Aronoff S,Rosenblatt S,Braithwaite S,et al.Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes:A 6-month randomized placebo-controlled dose-response study.The Pioglitazone 001 Study Group[J].Diabetes Care,2000,23:1605-1611.
[69]Nissen SE,Wolski K.Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes[J].N Engl JMed,2007,356:2457-2471.
[70]Dormandy JA,Charbonnel B,Eckland DJ,et al.PROactive Investigators:Secondary prevention of macrovascular events in patients with type 2 diabetes in the proactive study(prospective pioglitazone clinical trial in macrovascular events):A randomised controlled trial[J].Lancet,2005,366:1279-1289.
[71]Nissen SE,Wolski K.Rosiglitazone revisited:An updated meta-analysis of risk for myocardial infarction and cardiovascular mortality[J].Arch Intern Med,2010,170:1191-1201.
[72]刘红缨,孙爱军,王时俊,等.丹参酚酸B通过激活过氧化体增殖物激活型受体γ抑制树突状细胞免疫成熟的作用及其机制[J].中国动脉硬化杂志,2011(3):265.
[73]王子超,赵丽娟.姜黄素对NAFLD大鼠肝组织PPAR-γ和NF-κB p65 mRNA及蛋白表达的影响[J].中国医科大学学报,2016,45(2):120-126.
[74]郭杨志,杜娟,李向民,等.黄连对糖尿病肾病大鼠肾脏NF-κB及PPAR-γ表达的影响[J].世界中医药,2017(4):171-174.
[75]平键,陈红云,周扬,等.毛蕊异黄酮上调过氧化物酶体增殖因子活化受体γ抑制大鼠肝星状细胞活化的研究[J].中国中药杂志,2015,40(12):2383-2388.
[76]朱磊.清肠化湿、益气健脾法序贯治疗溃疡性结肠炎疗效观察及调控PPAR-γ、NF-κB的实验研究[D].南京中医药大学,2009.
[77]沈宇清,贾典荣,曹云,等.通解口服液对MODS模型大鼠回肠PPAR-γ、AP-1、NF-κB表达的影响[J].江苏中医药,2015(4):78-81.
[78]朱向东,梅晓云,王燕,等.痛泻要方对溃疡性结肠炎大鼠结肠黏膜PPAR-γ基因和蛋白表达的影响[J].中华中医药杂志,2013(4):941-945.
[79]王洁,王亚南,陆妍,等.藤莓汤对胶原诱导性关节炎大鼠滑膜PPARγ/NF-κB信号途径的影响[J].中国中西医结合杂志,2017(4):75-80.